The prognostic value of SGLT2 inhibitors in patients presenting with ST-segment elevation myocardial infarction with preserved LV systolic function | ||
| Benha Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 15 January 2025 PDF (561.41 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2024.335914.2252 | ||
| Authors | ||
| Hany H. Ebaid1; Maged Kh. Mahmoud* 2; Khaled E. Elrabbat3; Amr Elmordy Elsayed4 | ||
| 1Assistant professor of Cardiology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| 2MSc Cardiology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| 3Professor of Cardiology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| 4Lecturer of Cardiology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| Abstract | ||
| Background: Acute STEMI presents a range of risks for recurrent myocardial infarction, chronic heart failure, and cardiovascular death. Early post-infarction treatment strategies aim to reduce adverse cardiac remodeling and prevent long-term complications like chronic HF and sudden cardiac death. SGLT2 inhibitors, such as Dapagliflozin, have shown potential in modulating ventricular remodeling, suggesting benefits in post-MI management. Aim: This study aimed to evaluate the effects of adding Dapagliflozin to standard post-MI care on morbidity and mortality in patients with acute STEMI and preserved LV systolic function, regardless of diabetic status. Subjects and Methods: Three hundred patients with acute STEMI were randomized into two groups (Group I and II, 150 each). Group I received Dapagliflozin 10 mg orally once, followed by a daily dose of 10 mg, in addition to standard post-MI therapies. Comprehensive assessments, including medical history, clinical examination, electrocardiogram, and echocardiography, were conducted for all participants. Results: The average age of participants was 54 ± 11 years, with 59% male. A significant proportion had diabetes (42%) and hypertension (46%), and 50% were smokers. Group I showed significantly lower rates of recurrent AMI (2% = vs. 12%, P < 0.001), heart failure hospitalizations (4% vs. 14%, P = 0.002), and major adverse cardiac events (6% vs. 27.3%, P < 0.001). However, there were no significant differences in mortality (P = 0.498) or stroke (P = 0.498). Conclusion: Early addition of Dapagliflozin to standard post-STEMI care significantly reduced heart failure hospitalizations and MACE but had no impact on mortality or stroke outcomes. | ||
| Keywords | ||
| ST-segment elevation myocardial infarction (STEMI); SGLT2 inhibitors; Heart failure (HF) | ||
|
Statistics Article View: 47 PDF Download: 44 |
||
